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Abstract
Purpose There is a well-established research base surrounding face recognition in patients with age-related macular degeneration
(AMD). However, much of this existing research does not differentiate between results obtained for ‘wet’AMD and ‘dry’AMD.
Here, we test the hypothesis that face recognition performance is worse in patients with dry AMD compared with visually healthy
peers.
Methods Patients (>60 years of age, logMAR binocular visual acuity 0.7 or better) with dry AMD of varying severity and
visually healthy age-related peers (controls) completed a modified version of the Cambridge Face Memory Test (CFMT).
Percentage of correctly identified faces was used as an outcome measure for performance for each participant. A 90% normative
reference limit was generated from the distribution of CFMT scores recorded in the visually healthy controls. Scores for AMD
participants were then specifically compared to this limit, and comparisons between average scores in the AMD severity groups
were investigated.
Results Thirty patients (median [interquartile range] age of 76 [70, 79] years) and 34 controls (median age of 70 [64, 75] years)
were examined. Four, seventeen and nine patients were classified as having early, intermediate and late AMD (geographic
atrophy) respectively. Five (17%) patients recorded a face recognition performance worse than the 90% limit (Fisher’s exact
test, p = 0.46) set by controls; four of these had geographic atrophy. Patients with geographic atrophy identified fewer faces on
average (±SD) (61% ± 22%) than those with early and intermediate AMD (75 ± 11%) and controls (74% ± 11%).
Conclusions People with dry AMD may not suffer from problems with face recognition until the disease is in its later stages;
those with late AMD (geographic atrophy) are likely to have difficulty recognising faces. The results from this study should
influence the management and expectations of patients with dry AMD in both community practice and hospital clinics.
Keywords Lowvision .Facerecognition .Age-relatedmaculardegeneration .Geographicatrophy .Visual function .Activitiesof
daily living
Introduction
Face recognition is an important daily activity. We are be-
lieved to spend more time looking at faces than any other
complex visual stimuli, and this is central to social interactions
[1]. Difficulties with face recognition can lead to embarrass-
ment and anxiety in social situations, which in turn can lead to
social isolation [2]. People with age-related macular
degeneration (AMD) have difficulty with different aspects of
face recognition. For example, in a survey of 30 people with
bilateral AMD, all but one reported difficulty recognising fa-
miliar faces on the street; a third of these felt embarrassment as
a result [3]. In the same study, over half of respondents report-
ed missing things in conversation because of an inability to
make out facial expressions. These patient-reported data are
corroborated by performance-based research studies. For ex-
ample, viewing distances required for recognising faces were
found to be shorter on average for people with AMD than
those without [4]; moreover, the ability to determine whether
or not a face is expressive has been reported to be closely
related to near reading acuity [3]. In another study [5], only
26% of 100 people with AMD were able to correctly identify
the facial expression in four photographs of people depicting
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feelings such as happiness, sadness and tiredness; perfor-
mance in this task was related to visual acuity (VA) in the
participants, with those with poorest VA performing particu-
larly badly.
Age-related macular degeneration may be divided into vari-
ous stages. Early and intermediate [iAMD] AMD are
characterised by yellow/white deposits (drusen) beneath the ret-
inal pigment epithelium and/or areas of focal hyperpigmentation
or hypopigmentation. Later stages may take one of two forms:
neovascular AMD (nAMD), characterised by growth of new
blood vessels beneath the retina with a tendency to leak, causing
sudden vision loss; or geographic atrophy (GA), characterised
by sharply demarcated areas of hypopigmentation caused by
atrophy, causing more insidious vision loss [6, 7]. Neovascular
AMD is often referred to as ‘wet’, whilst non-neovascular AMD
(i.e. early and intermediate AMD and GA) may also be known
as ‘dry’AMD, and constitutes about 90% of diagnosed cases of
AMD [8].
Dry and wet AMD have been reported to differ in both their
functional [9] and psychological effects [10, 11]. There is a
growing interest in characterising the clinical features of dif-
ferent stages of dry AMD, particularly with respect to deter-
mining meaningful end points for clinical trials [12]. This
interest is timely, as there are several potential therapies for
dry AMD currently reaching the stage of phase III randomised
clinical trials (RCTs) [12]. Understanding the functional abil-
ity associated with each stage of dry AMD is a key element of
this characterisation of dry AMD progression. Previous re-
search on face recognition in AMD, however, has largely fo-
cused on people with wet AMD or has not differentiated be-
tween patients with wet and dry AMD [3, 5, 13]. The aim of
this study, therefore, was to investigate face recognition per-
formance in patients with dry AMD of varying severity com-
pared with visually healthy peers.
Methods
People with dry AMD were recruited from Moorfields Eye
Hospital Trust, London, optometrists local to the university
and the membership of the Macular Society (https://www.
macularsociety.org/). Patients were required to be ≥60 years
of age, have sufficiently clear ocular media (grade < 3 on the
Lens Opacities Classification System III grading scale [14]),
have adequate pupillary dilation and fixation to allow quality
fundus imaging, and to have dry AMD (early/intermediate/
late) in their better-seeing eye (assessed by visual acuity
[VA]). Fellow eyes of patients were permitted to be of any
AMD status. Binocular VA of logMAR 0.7 or better
(Snellen equivalent of 6/30) was required. Patients were ex-
cluded if they had nAMD in their better-seeing eye, had any
ocular or systemic disease that could affect visual function or
history of medication known to affect visual function (e.g.
tamoxifen or chloroquine), high risk of angle closure during
pupillary dilation (Van Herick < grade 2, history of angle
closure or experience of prodromal symptoms of angle clo-
sure). In addition, patients were required to pass an abridged
version of the Mini-Mental State Examination [15] and to
have sufficient knowledge of the English language to carry
out history and symptoms questioning and to understand test
instructions.
Age-related controls with healthy vision were recruited
from the City Sight Optometry Clinic at City, University of
London. People attending this clinic for eye examinations are
given the option to agree to be contacted if they wish to be
recruited for research studies. Eligibility criteria for controls
were the same as for AMD patients, except participants were
required to have no AMD (or any other eye disease) in either
eye, and monocular VA of logMAR 0.3 (6/12) or better.
The study was approved by a National Health Service
Research Ethics Committee and was conducted according to
the tenets of the Declaration of Helsinki. Written informed
consent was obtained from each participant before examina-
tion. Participant information was anonymised before being
entered into a secure computer database.
Clinical tests
Structured history and symptoms were taken. Best-corrected
VAwas tested using the Early Treatment Diabetic Retinopathy
Study (ETDRS) chart (this was scored per letter, and a
logMAR score was assigned), and contrast sensitivity (CS)
with the Pelli-Robson chart (this was also scored per letter,
and a logCS score was assigned). The Van Herick technique
was used to assess the anterior chamber angle. Dilated fundus
examination was conducted. Lens clarity was graded using a
slit lamp biomicroscope, according to the Lens Opacities
Classification System III grading scale [14]. Digital colour
fundus photographs were obtained, and these were used to
classify and grade AMD status by the better-seeing eye (de-
termined byVA) as early, intermediate, or late according to the
Beckman classification scale. [6] Spectral-domain optical co-
herence tomography (OCT) and fundus autofluorescence im-
ages were also taken; these, along with slit lamp indirect oph-
thalmoscopy, were used to support results obtained using col-
our fundus photographs—for example, OCT to confirm the
presence of nAMD, or fundus autofluorescence to confirm the
presence of GA.
Testing procedure
Face recognition was measured binocularly using a modified
version of the Cambridge Face Memory Test (CFMT) [16]
incorporating eye tracking used in our previous research stud-
ies [17, 18]. This was displayed on a 22-inch monitor (Iiyama
Vision Master PRO 514; Iiyama Corp., Tokyo, Japan; 1600 ×
816 Graefes Arch Clin Exp Ophthalmol (2018) 256:815–821
1200 pixels at 100 Hz). The monitor was placed 60 cm from
participants (viewing position was fixed using a head and chin
rest), subtending a visual angle of 36.9° horizontally and 28.1°
vertically. Images were displayed at an average luminance of
4.29 cd/m2 (SD, 1.16). On average, the faces subtended 7.4°
horizontally and 11.1° vertically. The average half-angle of
faces was 3.7° (equivalent of 6.5 cm width half-face). This
is comparable to the size of a face viewed in the real world at
approximately 1m. Optimal refractive correction for the view-
ing distance was determined by the operator (an optometrist;
DJT) prior to testing, and participants all wore this correction
mounted in a trial frame. This ensured that any effects caused
by frame edges and lens size would be equivalent for each
participant.
Instructions for the test were both written in large print on
the computer screen and given verbally. Trials involved a
viewing phase during which participants were shown a series
of faces (front and right and left side views) for 3 s per view,
and a selection phase during which participants were given a
forced-choice task of selecting which face from a set of three
matched the one they had just viewed. Responses were keyed
in by the operator (DJT). Participants were allowed unlimited
time during the ‘selection phase’. Participants completed six
trials in this manner (see Fig. 1).
Next, a montage of the six faces learnt during the preceding
trials was shown (the ‘review phase’), and participants were
asked to study them for 20 s. Recognition of these six faces
was then tested by showing participant sets of three faces and
requiring them to select the one they had seen before (forced
choice again). Overall, participants completed 51 trials.
Analysis
The percentage of correctly identified faces across the 51 trials
was used as the performance outcome measure (FR score) for
each participant. A 90% normative reference limit was gener-
ated from the distribution of ranked scores recorded in the
visually healthy controls. This limit was estimated by a direct
percentile method [19]. Scores for AMD participants were
then specifically compared to this limit and comparisons made
between groups of patients based on severity of AMD in the
better-seeing eye. Scores for AMD participants were then spe-
cifically compared to this limit and comparisons made be-
tween groups of patients based on severity of AMD in the
better-seeing eye. This was explored graphically, and
Fisher’s exact test was used to test whether the proportion of
AMD patients falling outside this limit differed from the pro-
portion of controls falling outside the limit (10%). Amongst
people with GA, the relationship between lesion area (as mea-
sured using Spectralis RegionFinder software (Heidelberg
Engineering, Heidelberg, Germany) and presence/absence of
foveal sparing and FR score were explored, again comparing
scores to the normative limit set by controls. Mean scores
were also calculated for each AMD severity group, and com-
parisons were made between groups and to mean scores in the
visually healthy controls using one-way analysis of variance
(ANOVA) and one-way analysis of covariance (ANCOVA)
where applicable. Univariate associations between FR score
and self-reported disease duration, VA, CS and age were ex-
plored. All statistical analysis was conducted in SPSS version
22 software (IBM Corp., Armonk, NY).
Fig. 1 An example task from the
selection phase of the Cambridge
Face Memory Test (CFMT).
Participants were asked to
familiarise themselves with a
face, shown from three different
viewpoints (a, b and c).
Participants were then asked to
tell the operator which face
matched the one they had just
viewed (d). Image adapted from
Duchaine et al. (2006) [16] with
permission from Elsevier
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Results
Thirty participants with AMD (87% female) with a median
(interquartile range [IQR]) age of 76 (70–79) years, and 34
visually healthy controls (53% female) with a median age of
70 (64–75) years, took part in our study. The median (IQR)
duration of AMD was 4 (2–6) years. Participants were of
reasonably good general health (ascertained by structured his-
tory and symptoms). The median (IQR) ETDRS corrected
binocular logMAR VA was 0.22 (0.18–0.38) and −0.06
(−0.12–0) in patients and controls, respectively. The median
(IQR) Pelli-Robson logCS values were 1.65 (1.35–1.95) and
1.95 (1.95–1.95) in patients and controls, respectively.
When stratified according to the Beckman classification for
the better-seeing eye (no participants had equal VA between
eyes), four, seventeen and nine patients were classified as
having early, intermediate and late AMD (GA), respectively
[6]. Median (IQR) ETDRS corrected binocular logMAR VA
according to AMD stage was 0.20 (0.19–0.26), 0.20 (0.13–
0.28), and 0.36 (0.24–0.57) for people with early, intermedi-
ate, and late AMD respectively. Table 1 shows AMD classifi-
cation for fellow eyes.
Five (17%) patients recorded a face recognition performance
worse than the 90% limit set by controls (Fig. 2). This proportion
of AMD patients, as a whole sample, did not differ significantly
from the proportion of controls falling outside the limit (Fisher’s
exact test, p = 0.46). However, four of the five patients falling
outside the 90% limit set by the controls had GA.
Amongst people with GA, those with larger GA lesion area
and foveal involvement scored worse on the CFMT than those
with smaller lesion area and foveal sparing (Fig. 3). Of the
four participants with GAwho fell outside the normative limit
for FR score set by controls, all had foveal-involving GA and
larger lesions than those who fell within the normative limit.
When considering mean effects across the groups, patients
with GA identified fewer faces on average (± standard devia-
tion [SD]) (61 ± 22%) than those with early and intermediate
(75 ± 11%) AMD and controls (74 ± 11%); this difference was
statistically significant (one-way ANOVA, p = 0.04). There
was a correlation between age and FR score amongst controls
(r = −0.43, p = 0.01), so we corrected our analysis to accom-
modate for age as a covariate, but the statistical significance of
the effect of patients with GA performing worse on CFMT
than other groups clearly remained (ANCOVA, p = 0.007). No
statistically significant differences between groups were ob-
served when participants were grouped according to fellow-
eye AMD classification (one-way ANOVA, p = 0.39).
Amongst patients, there was a strong statistically signifi-
cant correlation between FR score and CS (r = 0.63, p <
0.001), and a weaker but statistically significant correlation
between FR score and VA (r = −0.54, p = 0.002; Fig. 4).
There was no significant correlation between AMD duration
and CFMT score (r = −0.23, p = 0.25).
Discussion
We studied computer-based face recognition performance in
patients with a range of severities of dry AMD compared with
visually healthy peers. It is well documented that people with
AMD have difficulty with face recognition. Our study adds to
this knowledge, because it is the first study to document face
recognition performance specifically in people with dry AMD.
Moreover, we compare FR performance, using a validated test
[16], in people with different stages of AMD, as classified by a
widely used grading scale [6]. Our results indicate that people
with early or intermediate dry AMD perform as well as visually
healthy peers on a controlled face recognition task. Therefore,
patients with dry AMDmay not typically suffer from problems
with recognising faces until the disease is in its later stages;
those with late AMD (GA) in their least affected eye are likely
to have difficulty recognising faces.
Our results are most comparable with a previous study we
conducted in people with glaucoma. In our previous work in
glaucoma using the CFMT, patients with mild and moderate
glaucomatous visual field loss [20] were found to have similar
face recognition performance to those without, whilst those
with advanced glaucomatous visual field loss were found to
have worse face recognition ability. Similarly, in our current
study, we report that patients with advanced AMD (GA) have
poorer face recognition ability, on average, than those with
early and intermediate AMD and those without AMD.
However, participants with GA in this study scored worse
on average (mean ± SD [61% ± 22%]) than those with ad-
vanced glaucomatous visual field loss in our previous study
(66% ± 15%), indicating that patients with advanced dry
Table 1 AMD severity in fellow
eyes according to better-eye status Classification of better-
seeing eye
Fellow eye classification
Early AMD,
no.
Intermediate
AMD, no.
Late AMD (GA),
no.
Late AMD
(nAMD), no.
Early AMD 4
Intermediate AMD 11 3 3
Late AMD (GA) 8 1
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AMD may have greater difficulty with face recognition than
those with advanced glaucoma.
Thewide variation in FR scores across our results agreeswith
previous work on face recognition in AMD. Barnes et al. (2011)
[13] tested a group of people with AMD with visual character-
istics similar to those of our participants (median logMARVAof
0.20 and CS of 1.55). Awide variability in FR scores was noted,
although people with AMD had poorer face recognition on av-
erage than did visually healthy controls. Classification and stage
of AMD was not reported. A large-scale US-based survey of
people with AMD [21] reported a fairly even spread across
response options for two of the three items on the Daily
Living Tasks Dependent on Vision (DLTV) Questionnaire
relating to face recognition. These items described the difficulty
experienced in distinguishing a person’s features across a room
and across the street. The third item on this questionnaire relat-
ing to face recognition asked respondents about difficulty in
distinguishing a person’s features at arm’s length. A much
higher proportion of respondents (61%) reported ‘no difficulty
at all’ for this item compared to the other items; this is relevant to
our findings because this item likely reflects difficulty under a
task condition most similar to that presented by the CFMT
(comparable to viewing a face at 1 m). However, further com-
parisonwith our study is limited by the fact that the survey study
did not report AMD stage or classification.
We showed a strong association between worsening FR
performance and worsening of measured CS in patients with
dry AMD. Current evidence surrounding the relationship be-
tween FR performance and CS in AMD is conflicting. Some
studies [3, 4] report a weak relationship, whilst others report a
strong relationship [13, 22]. Other papers have suggested that
CS is a more useful indicator of performance of everyday
activities [5], mobility [23, 24] and quality of life [25] in people
with AMD than other traditional measures of visual function,
certainly more than visual acuity alone. However, in a study
investigating clinical tests perceived as most and least impor-
tant by ophthalmologists (albeit almost 20 years ago), CS was
consistently rated as one of the least important clinical tests of
vision [26]. Our study not only adds to the body of evidence
supporting the relationship between FR performance andCS in
AMD, but also supports the suggestion that CS may be a more
valuable predictor of real-world visual performance than high-
contrast VA alone. Median logMARVAvalues for participants
with early and intermediate AMD (each 0.20) were found to be
worse than those of controls (−0.06) in this study. This aligns
with VA findings from previous research involving individuals
at a similar disease stage [27, 28]. We have also shown that
foveal involvement of GA and GA lesion area may be useful
predictors of face recognition performance. This implies that
the ability to accurately recognise faces is highly dependent on
the fovea remaining intact, and provides further evidence to
support the development of treatments which may halt or slow
the progression of GA before the fovea is affected, such as
those currently undergoing clinical trials [12].
Our study has limitations. Although all participants were
screened for cognitive defects, it is possible that subtle differ-
ences in cognitive ability between participants may have affect-
ed the results. Another limitation of this work—and indeed of
most face recognition testing—is the questionability of its real-
world applicability. The CFMT was chosen for this work be-
cause of its strengths compared with other face recognition tests
available at the time of testing, its wide use and acceptability
(over 300 citations in peer-reviewed literature), its reliability
(previous research has consistently confirmed the reliability of
the CFMT [Cronbach’s α > 0.8] [29–31]), and specifically its
previous use in testing face recognition in eye disease [17, 18].
Fig. 3 Scatter plot showing the relationship between FR score and GA
lesion size amongst participants with dry AMD, colour-coded according
to whether foveal sparing was present or not. The dotted black line
represents the 90% normative limit derived from the visually healthy
controls
Fig. 2 Percentage Cambridge Face Memory Test (CFMT) score for each
participant stratified by AMD group. The 90% normative limits set by
controls are illustrated by the darker shaded area on the right of both
graphs. (Some vertical jitter is added to the plotted points.)
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However, previous research (using different testing methodol-
ogy) has found a poor relationship between perceived face rec-
ognition ability (self-reported difficulties in face recognition
reported by almost all participants in the particular study) and
performance on a face recognition task [3]. A number of theo-
ries attempt to explain these discrepancies. They may occur as a
result of differing conditions in the real world, for example,
differences in luminance at different times of day and indoors
versus outdoors, and differences in viewing distance [32, 33].
Current face recognition testing modalities may not be sensitive
enough to detect subtle differences in face recognition ability
across people with eye disease of varying severity. A newer test
[34] claims to be potentially more sensitive to subtle differences
in face discrimination ability than other tests, including the
CFMT. Future work might test this further.
There are other potential limitations to our findings. The
patients with AMD in our study were very slightly older on
average than their visually healthy peers (the 95% confidence
interval for mean difference in age was 2–8 years.) However, we
corrected our results for this, and it made no difference in our
findings. Finally, the fact that 87%of our participants withAMD
were female, whilst the control group was only 53% female,
might be seen as a limitation. However, the CFMTwas designed
specifically with male faces, as opposed to female faces or a
mixture, because men and women have been shown to exhibit
equal FR performance for men’s faces. [16] Therefore, we do
not believe that this has influenced the results of our study.
An easily administered and shortened version of the CFMT
face recognition task based on our work might have a role as
an outcome measure for clinical trials. Our results suggest that
the test would not be sensitive to changes in the early and
intermediate stages of AMD, but might spotlight a meaningful
functional end point when patients develop GA. Results from
this type of test are likely to be more meaningful to patients
than traditional outcome measures such as letter charts, where
changes are often imperceptible to the patient. Development
of such a test is the subject of our future work.
To conclude, people with dry AMD may not suffer from
problems with face recognition until the disease is in its later
stages; those with late AMD (GA), particularly those with
larger areas of atrophy involving the fovea and those with
significantly reduced CS and (to a lesser extent) visual acuity,
are likely to have difficulty recognising faces. This could have
important implications for patients, especially when coupled
with other problems associated with age-related macular de-
generation, for example, difficulties and fears surrounding
mobility [35]. The results from this study should influence
both management and expectations of patients with dry AMD.
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